Skip to content

Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis

Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06180551
Acronym
RESCUE-AKI
Enrollment
1000
Registered
2023-12-22
Start date
2023-12-01
Completion date
2027-06-30
Last updated
2023-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Brief summary

Critically ill patients are at risk of developing a sudden decrease of kidney function which may be detected by a decrease in urine output or is diagnosed on the basis of blood tests for substances normally eliminated by the kidney, primarily creatinine. Because it takes about 24 hours for the creatinine level to rise, even if both kidneys have ceased to function, better markers are needed. This trial is investigating if the marker urinary dickkopf-3 (uDKK3) allows an early prediction of a sudden decrease of kidney function.

Detailed description

Urinary dickkopf-3 (uDKK3), a stress-induced renal tubular epithelium-derived glycoprotein, has been identified as a biomarker predicting persistent kidney dysfunction. In this prospective observational trial in patients at high risk of developing acute kidney injury we will assess whether urinary dickkopf-3 serves as a predictor of acute kidney injury. Patients of the intensive care units of Saarland University Hospital will be surveyed for up to two years after their admission to the intensive care unit. The progression of the estimated Glomerular Filtration Rate and uDKK3 will be monitored.

Interventions

DIAGNOSTIC_TESTDKK-3

DKK-3-Urine measurement

Sponsors

Universität des Saarlandes
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients treated on the intensive care units of Saarland University Hospital.

Exclusion criteria

* Patients on renal replacement treatment before admission to the intensive care unit. * Patients with chronic kidney disease stage CKD G3b or below. * Known kidney disease. * Kidney transplantation. * Intoxications leading to dialysis treatment. * Participation in other clinical trials.

Design outcomes

Primary

MeasureTime frameDescription
Urinary dickkopf-3Throughout observational period, defined as timeframe from admission to intensive care unit up to two years after.Urinary dickkopf-3
Estimated Glomerula Filtration RateThroughout observational period, defined as timeframe from admission to intensive care unit up to two years after.Estimated Glomerula Filtration Rate by CKD-EPI-formula.

Secondary

MeasureTime frameDescription
Length of renal replacement therapyDuring the ICU stay.Length of time patients receive renal replacement therapy for chronic kidney injury.
MortalityThroughout observational period, defined as timeframe from admission to intensive care unit up to two years after.Number of patients who die during the observational period.
End Stage Renal DiseaseThroughout observational period, defined as timeframe from admission to intensive care unit up to two years after.Number of patients with initiation of chronic kidney replacement therapy (maintenance dialysis or kidney transplantation).

Countries

Germany

Contacts

Primary ContactStefan Neuhaus, MD
stefan.neuhaus@uks.eu+4968411615041

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026